Ondansetron Augmentation of Serotonin Reuptake Inhibitors as a Treatment Strategy in Obsessive-Compulsive Disorder

Andrade, Chittaranjan

doi:10.4088/jcp.14f09704

Cited by 10 publications

(4 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, ondansetron was given at higher doses in RCTs [222,223] vs. uncontrolled studies [220,221]. Ondansetron (1-8 mg/day) is a potential augmenting agent in patients for whom SGAs are problematic [224]. However, further studies are necessary to confirm these acquisitions, to establish long-term efficacy and safety, and to identify appropriate dosing and treatment duration.…”

Section: Ondansetronmentioning

confidence: 99%

Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)

Casale

Sorice²,

Padovano³

et al. 2019

147

View full text Add to dashboard Cite

show abstract

Section: Ondansetronmentioning

confidence: 99%

Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)

Casale

Sorice²,

Padovano³

et al. 2019

147

View full text Add to dashboard Cite

show abstract

“…Although the drug is currently undergoing phase 2−3 controlled trials, no meaningful results have been reported yet [ 38 ]. The efficacy of ondansetron, a 5-HT3 serotonin receptor antagonist, in the treatment of refractory OCD was significant in several RCTs with add-on to SSRIs [ 39 ]. Although further studies are necessary to confirm its long-term safety and efficacy, ondansetron was rated with the level of evidence A and recommendation level 2 as a potential augmenting agent [ 15 ].…”

Section: Advances In Treatment For Ocd In Adultsmentioning

confidence: 99%

Clinical Advances in Treatment Strategies for Obsessive-compulsive Disorder in Adults

Roh

Jang

Kim

2023

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

In the present article, we provide a comprehensive review of the treatment strategies for obsessive-compulsive disorder (OCD), a common, chronic, and often debilitating disorder, characterized by overwhelming obsessions and compulsions. OCD typically starts in childhood or adolescence and persists throughout life, causing functional impairment across multiple domains. The article begins by describing the historical concepts of OCD from religious and guilt-based explanations to psychoanalytic perspectives, and then explores the changing understanding of OCD as a treatable con-dition. Recent advances include the development of evidence-based psychological treatments, such as exposure and response prevention, and pharmacological treatments, such as selective serotonin reuptake inhibitors. The latest version of the Diagnostic and Statistical Manual of Mental Disorders, and the International Classification of Diseases, has removed OCD from the anxiety disorder grouping and regrouped it into obsessive-compulsive and related disorders. We conclude by highlighting the current state of knowledge and development in the clinical management of OCD, including recommendations for first- and second-line treatments, alternative, or augmentative strategies for and novel agents under investigation for OCD. In future, the latest advances in neuroimaging, electrophysiology, digital technology, and data-driven analysis will help elucidate the pathophysiology of OCD and develop personalized intervention strategies.

show abstract

“…Through 5-HT3 blockade, these drugs have a weak downstream inhibitory effect on dopaminergic neurotransmission. Ondansetron has been found to be effective in both uncontrolled and placebo-controlled trials [28,29], but the experience with ondansetron in our clinic has not been encouraging [30]. At best, 5HT-3 antagonists may be viewed as experimental treatments needing confirmation in larger studies.…”

Section: Other Augmenting Agentsmentioning

confidence: 99%